Regional Oesophago-Gastric Cancer Centre, Department of Upper Gastrointestinal Surgery, Broomfield Hospital, Chelmsford, Essex, U.K.
Upper Gastrointestinal and General Surgery Unit, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Anticancer Res. 2020 Mar;40(3):1753-1758. doi: 10.21873/anticanres.14129.
BACKGROUND/AIM: Esophagectomy is a major surgical procedure associated with a significant risk of morbidity and mortality that has traditionally been performed by an open approach. Although minimally invasive procedures for benign esophageal disease have been widely accepted worldwide, they have not yet been established for the treatment of malignancy.
A total of 137 consecutive hybrid esophagectomies for cancer were performed by the same surgical team. Surgical approach included either 2-stage or 3-stage hybrid minimally-invasive esophagectomy.
Median age of patients was 64 years. Respiratory complication and anastomotic leak rates were 16.78% and 9.48%, respectively. Median follow-up was 48 months with median overall survival and disease free survival were 58 and 48 months, respectively.
Advances in minimally invasive surgery can benefit patients with esophageal cancer, mainly by reducing post-operative respiratory complications. Hybrid esophagectomy is safe and feasible in tertiary esophago-gastric centers with vast expertise that can lead to improved clinical and oncological outcomes.
背景/目的：食管癌切除术是一种与较高发病率和死亡率相关的主要外科手术，传统上采用开放方法进行。尽管微创治疗良性食管疾病的方法已在全球范围内得到广泛认可，但它们尚未应用于恶性肿瘤的治疗。
同一手术团队共对 137 例连续的食管癌进行了杂交食管癌切除术。手术方法包括两阶段或三阶段杂交微创食管癌切除术。
患者的中位年龄为 64 岁。呼吸并发症和吻合口漏的发生率分别为 16.78%和 9.48%。中位随访时间为 48 个月，中位总生存期和无病生存期分别为 58 个月和 48 个月。
微创外科技术的进步可以使食管癌患者受益，主要是通过减少术后呼吸并发症。杂交食管癌切除术在具有丰富专业知识的三级食管胃中心是安全可行的，可导致临床和肿瘤学结果的改善。
